Climb Bio (CLYM) Cash & Equivalents (2020 - 2026)

Climb Bio has reported Cash & Equivalents for 7 years, with the latest figure at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 71.21% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (down 71.21% YoY), and the FY2025 full-year result was $35.7 million, down 59.09% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $8.4 million, down from $35.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $223.1 million in Q2 2024, with the low at $8.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $92.7 million across 5 years, with a median of $99.7 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 274.05% — and 2025, when it tumbled 89.84%.
• Climb Bio's Cash & Equivalents stood at $107.5 million in 2022, then decreased by 13.35% to $93.1 million in 2023, then dropped by 6.32% to $87.2 million in 2024, then slumped by 59.09% to $35.7 million in 2025, then sank by 76.58% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $35.7 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.